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Hereditary hemochromatosis (HH) is characterized by increased intestinal iron absorption
that may result in iron overload. Although phlebotomy is widely practiced, it is poorly tol-
erated or contraindicated in patients with anemias, severe heart disease, or poor venous
access, and compliance can vary. The once-daily, oral iron chelator, deferasirox (Exjade)
may provide an alternative treatment option. Patients with HH carrying the HFE gene
who were homozygous for the Cys282Tyr mutation, serum ferritin levels of 300-2000 ng/
mL, transferrin saturation  45%, and no known history of cirrhosis were enrolled in this
dose-escalation study to characterize the safety and efﬁcacy of deferasirox, comprising a
core and an extension phase (each 24 weeks). Forty-nine patients were enrolled and
received starting deferasirox doses of 5 (n 5 11), 10 (n 5 15), or 15 (n 5 23) mg/kg/day.
Adverse events were generally dose-dependent, the most common being diarrhea, head-
ache, and nausea (n 5 18, n 5 10, and n 5 8 in the core and n 5 1, n 5 1, and n 5 0i n
the extension, respectively). More patients in the 15 mg/kg/day than in the 5 or 10 mg/kg/
day cohorts experienced increases in alanine aminotransferase and serum creatinine levels
during the 48-week treatment period; six patients had alanine aminotransferase >33 base-
line and greater than the upper limit of normal range, and eight patients had serum creati-
nine >33% above baseline and greater than upper limit of normal on two consecutive
occasions. After receiving deferasirox for 48 weeks, median serum ferritin levels decreased
by 63.5%, 74.8%, and 74.1% in the 5, 10, and 15 mg/kg/day cohorts, respectively. In all
cohorts, median serum ferritin decreased to <250 ng/mL. Conclusion: Deferasirox doses of
5, 10, and 15 mg/kg/day can reduce iron burden in patients with HH. Based on the safety
and efﬁcacy results, starting deferasirox at 10 mg/kg/day appears to be most appropriate
for further study in this patient population. (HEPATOLOGY 2010;52:1671-1679)
H
ereditary hemochromatosis (HH) is one of
the most common genetic diseases, and most
patients are homozygous for the HH gene
HFE Cys282Tyr (C282Y) mutation. Homozygosity
for C282Y may be associated with excessive absorption
of dietary iron in some cases. If untreated, progressive
iron accumulation in key organs leads to toxicity,
resulting in tissue damage and organ dysfunction.
1-3
Patients with HH and cirrhosis are also at signiﬁcant
risk of developing hepatocellular carcinoma.
4 Iron over-
load can be readily managed in most patients by thera-
peutic phlebotomy. However, patients with underlying
anemias, severe heart disease, or reduced venous access
may not tolerate this form of treatment.
5 In addition,
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C282Y, cysteine-to-tyrosine mutation at position 282; HH,
hereditary hemochromatosis; ULN, upper limit of normal
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1671compliance may also be variable over time
6 as a result of
the inconvenience of frequent clinic visits and the dis-
comfort associated with the procedure.
The once-daily oral iron chelator deferasirox (Exjade;
Novartis Pharma AG, Basel, Switzerland) is indicated
for the treatment of chronic iron overload due to fre-
quent blood transfusions at approved doses of 10-40
mg/kg body weight/day. Clinical studies have demon-
strated the efﬁcacy, safety, and tolerability of deferasirox
in patients with a variety of conditions associated with
transfusional iron overload.
7-11 Studies reporting iron
chelation therapy in patients with primary (nontransfu-
sional) iron overload are limited, but data are encourag-
ing.
12-16 As patients with HH generally have a lower rel-
ative iron burden than those with transfusional iron
overload and do not accumulate iron at the same rate,
the safety and efﬁcacy of iron chelation therapy in this
setting requires further evaluation. The current study is
the ﬁrst clinical trial to assess the safety and efﬁcacy of
deferasirox therapy (at the lower end of the approved
dose range for patients with transfusional iron overload)
in patients with HH who required de-ironing based on
elevated serum ferritin levels.
Patients and Methods
Patient Recruitment. The study was conducted
across 18 sites in six countries (United States, France,
Germany, Italy, Australia, and Canada). This was an
open-label, multicenter, dose-escalation study designed
to characterize the safety and efﬁcacy of deferasirox
using four dose levels (5, 10, 15, and 20 mg/kg/day).
Male and female patients (aged  18 years) with
homozygosity for the C282Y HFE mutation (as docu-
mented by molecular diagnostic testing) and iron over-
load (as shown by serum ferritin levels of 300-2000
ng/mL and serum transferrin saturation  45%) were
included in the study. Key exclusion criteria were:
males with hemoglobin concentrations <13 g/dL or
females with hemoglobin concentrations <12 g/dL;
treatment with phlebotomy within 2 weeks of screen-
ing; history of blood transfusion during the 6 months
prior to study entry; current or previous treatment
with deferiprone (Ferriprox; Apotex, Inc., Toronto,
ON, Canada) or deferasirox; serum creatinine levels
above the upper limit of the normal range (ULN); ala-
nine aminotransferase (ALT) levels of  2  ULN; or
known diagnosis of liver cirrhosis. All patients pro-
vided written, informed consent at the start of the
core and extension periods of the study. The study was
conducted in accordance with Good Clinical Practice
guidelines and the Declaration of Helsinki.
Study Design. After all eligibility criteria had been
conﬁrmed, at least eight patients were planned to be en-
rolled in each of the four dose levels in a sequential
manner. Opening of the next dose level (dose escalation)
followed a safety review by an independent safety moni-
toring committee; this was conducted once the sixth
patient enrolled in that stratum had been treated for 4
weeks. Dose escalation was guided by a Bayesian logistic
regression model
17,18 for the most common severe
adverse events (AEs; abdominal pain, nausea, vomiting,
diarrhea, rash, increased serum creatinine, and increased
aminotransferases) and clinical review. The recom-
mended dose level at completion of the core study was
based on an overall assessment of safety and efﬁcacy,
taking into account all tolerability and serum ferritin
data collected at each dose level tested. At the end of the
core period of 24 weeks, patients were invited to enter
an extension study for a further 24 weeks of therapy
with deferasirox. Patients who chose not to continue the
study did not have to provide a reason.
Assessments. The primary objective of the core study
was to assess the safety of deferasirox therapy, with con-
tinued assessment in the 24-week extension phase.
Safety assessments consisted of monitoring and record-
ing all AEs (including serious AEs), the regular monitor-
ing of biochemistry, hematology, urinalysis, electrocar-
diogram, audiometry, and ocular examination data. The
effect of deferasirox therapy on serum ferritin levels was
assessed as a secondary objective. If serum ferritin levels
fell to <100 ng/mL at any visit, deferasirox was inter-
rupted until levels rose to >300 ng/mL. Serum ferritin,
serum iron, serum transferrin, calculated total iron-
binding capacity, and transferrin saturation parameters
were measured at screening and at each study visit.
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least one dose of study drug, and had at least one
post-baseline safety assessment, were included in the
safety population. The per-protocol population com-
prised patients from the safety population who had no
major protocol violations and was used for selected ef-
ﬁcacy analyses. Median decrease in serum ferritin levels
in the core and extension studies were analyzed based
on the signed-rank test for the three respective dose
cohorts. Changes in serum ferritin levels among the
three dose cohorts from baseline to end of study were
evaluated by performing an analysis of covariance,
where the baseline serum ferritin measure was ﬁtted as
a continuous covariate. A longitudinal analysis was
also performed by a linear mixed-effects model for se-
rum ferritin. The statistical model for the dose escala-
tion of deferasirox was based on a two-parameter logis-
tic model.
Results
Patient Characteristics. A total of 49 Caucasian
patients with HH were enrolled in the core study
(Table 1) and received starting doses of deferasirox of
either 5 (n ¼ 11), 10 (n ¼ 15), or 15 (n ¼ 23) mg/
kg/day for at least 24 weeks. The study was initiated
on August 23, 2006, and completed on October 2,
2008, and March 19, 2009, for the core and extension
study, respectively.
After 49 patients had been enrolled in the study and
23 patients had been treated at the 15 mg/kg/day dose
level, further dose escalation was stopped. The esti-
mated mean rate of the most common severe AEs at
20 mg/kg/day was determined to be 34.9% compared
with 17.4% at the 15 mg/kg/day dose level, suggesting
that dose escalation should not continue beyond 15
mg/kg/day. All 49 patients were included in the safety
analysis and 48 patients were included in the efﬁcacy
analysis (per-protocol; one patient was excluded due to
clinical evidence of active hepatitis B/C).
Thirty-seven (75.5%) patients completed the core
study (10 [90.9%], 11 [73.3%], and 16 [69.6%]
patients in the 5, 10, and 15 mg/kg/day cohorts,
respectively). Twenty-six patients decided to continue
into the extension study; 23 (88.5%) patients (nine
[100%], six [100%], eight [72.7%] patients in the 5,
10, and 15 mg/kg/day cohorts, respectively) completed
the 24-week extension.
Table 1. Patient Demographics and Characteristics at Baseline
Characteristic 5 mg/kg/day (n 5 11) 10 mg/kg/day (n 5 15) 15 mg/kg/day (n 5 23) All Patients (n 5 49)
Mean age 6 SD, years 55.8 6 12.8 47.8 6 10.3 49.8 6 16.4 50.6 6 14.0
Male:female 9:2 11:4 13:10 33:16
Mean time since diagnosis 6 SD, years 6.6 6 7.0 1.3 6 2.0 2.6 6 3.8 3.1 6 4.7
Median serum ferritin (range), ng/mL* 512 (376–1729) 859 (447–1792) 634 (357–1600) 645 (357–1792)
Mean transferrin saturation 6 SD, %* 78.1 6 17.4 81.0 6 12.7 74.1 6 15.4 77.2 6 15.2
*Based on the per-protocol population.
Fig. 1. Patient disposition in the core and extension study. *The 5 mg/kg/day dose reduced serum ferritin in only three patients; the other six
patients in this dose cohort received 10 mg/kg/day at the start of the extension (all but one patient experienced serum ferritin levels <100 ng/
mL when receiving 10 mg/kg/day).
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extension study, 15 patients discontinued treatment.
Reasons for discontinuation in the core study were:
protocol deviation (n ¼ 1) in the 5 mg/kg/day cohort;
AEs (n ¼ 3) and consent withdrawal (n ¼ 1) in the
10 mg/kg/day cohort; and AEs (n ¼ 4), consent with-
drawal, abnormal laboratory value and loss to follow-
up (n ¼ 1 for each) in the 15 mg/kg/day cohort (Fig.
1). In the extension study, three patients discontinued
in the 15 mg/kg/day cohort primarily due to AEs (n
¼ 2; Fig. 1). AEs leading to discontinuation were ALT
elevation, increased bilirubin levels (attributed to pre-
existing Gilbert’s syndrome; peak total bilirubin of
104.3 lmol/L) and diarrhea/nausea/backache/fatigue
in the core 10 mg/kg/day cohort (n ¼ 1 for each);
severe rash, serum creatinine elevation, nausea, and
ALT elevation in the core 15 mg/kg/day cohort (n ¼ 1
for each); and diarrhea and increased levels of serum
aminotransferases in the extension 15 mg/kg/day
cohort (n ¼ 1 for both).
Safety Assessment. The most common investigator-
reported AEs after the start of deferasirox treatment
( 10% in all patients) during the core study were di-
arrhea, headache, nausea, and abdominal pain (Table
2). Common AEs suspected to be drug-related ( 10%
in all patients) were diarrhea, nausea, and abdominal
pain (Table 3). There were no serious AEs or deaths
reported by the investigators. In the extension study,
the incidence of newly reported AEs and drug-related
AEs was reduced compared with the core study (Tables
2 and 3).
Over the entire study (48 weeks), more patients in
the 15 mg/kg/day cohort experienced increases in ALT
or aspartate aminotransferase (AST) levels >3  base-
line and greater than ULN than the lower dose cohorts
(Table 4). All eight patients who had ALT >3  base-
line and greater than ULN had their dose interrupted;
four discontinued the study, three did not restart, and
one was observed until the end of the core study but
did not enter the extension. Of these patients with
ALT or AST events, only one patient had an increase
in bilirubin greater than ULN.
In the core study, two patients had ALT levels >5 
ULN (both in the 15 mg/kg/day cohort; one patient
had elevated levels at baseline), and 11 patients had se-
rum creatinine levels >33% above baseline and greater
than ULN on two consecutive occasions (ﬁve patients
in the 10 mg/kg/day cohort and six patients in the 15
mg/kg/day cohort). In the extension study, one patient
experienced an increase in ALT levels >5  ULN (15
mg/kg/day cohort; levels were elevated at baseline),
and seven patients had serum creatinine levels >33%
above baseline and greater than ULN on two consecu-
tive occasions (two patients in the 10 mg/kg/day
cohort and ﬁve patients in the 15 mg/kg/day cohort).
Patients were managed with dose decreases and/or
interruptions.
Serum Ferritin and Transferrin Saturation. Of
the patients completing the core and extension study,
26 of 37 (70.3%) and 21 of 23 (91.3%) achieved se-
rum ferritin levels of <500 ng/mL. Of the 23 patients
completing 48 weeks of deferasirox treatment, 15
(65.2%) had serum ferritin levels of <250 ng/mL by
the end of the extension study. Four (36.4%), two
(13.3%), and eight (36.4%) patients (per-protocol)
had serum ferritin levels of <100 ng/mL in the 5, 10,
and 15 mg/kg/day cohorts, respectively, at some point
during the 48-week treatment period. Reductions in
serum ferritin levels were observed in the core study
across all three dose cohorts with a median decrease of
Table 2. Most Common AEs ( 10% of All Patients in Core or Extension)
Adverse Event
n (%)
5 mg/kg/day 10 mg/kg/day 15 mg/kg/day All Patients
Core (n 5 11) Ext (n 5 9) Core (n 5 15) Ext (n 5 6) Core (n 5 23) Ext (n 5 11) Core (n 5 49) Ext (n 5 26)
Diarrhea 2 (18.2) 0 6 (40.0) 0 10 (43.5) 1 (9.1) 18 (36.7) 1 (3.8)
Headache 1 (9.1) 0 2 (13.3) 0 7 (30.4) 1 (9.1) 10 (20.4) 1 (3.8)
Nausea 0 0 2 (13.3) 0 6 (26.1) 0 8 (16.3) 0
Abdominal pain 0 0 3 (20.0) 0 4 (17.4) 0 7 (14.3) 0
Increased serum creatinine* 0 1 (11.1) 3 (20.0) 1 (16.7) 4 (17.4) 1 (9.1) 7 (14.3) 3 (11.5)
Back pain 1 (9.1) 1 (11.1) 4 (26.7) 0 2 (8.7) 0 7 (14.3) 1 (3.8)
Increased ALT* 0 1 (11.1) 3 (20.0) 0 3 (13.0) 0 6 (12.2) 1 (3.8)
Rash 1 (9.1) 0 1 (6.7) 1 (16.7) 4 (17.4) 0 6 (12.2) 1 (3.8)
Flatulence 2 (18.2) 0 1 (6.7) 0 2 (8.7) 0 5 (10.2) 0
Nasopharyngitis 1 (9.1) 0 1 (6.7) 0 3 (13.0) 0 5 (10.2) 0
Fatigue 1 (9.1) 1 (11.1) 1 (6.7) 1 (16.7) 2 (8.7) 1 (9.1) 4 (8.2) 3 (11.5)
Arthralgia 1 (9.1) 0 2 (13.3) 2 (33.3) 1 (4.3) 1 (9.1) 4 (8.2) 3 (11.5)
*Reported based on clinical signs or symptoms, considered clinically signiﬁcant by investigator or requiring therapy as a result.
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0.0005), and 55.4% (P < 0.0001) in the 5, 10, and
15 mg/kg/day cohorts, respectively. The time course of
the serum ferritin decrease was dose-dependent (Fig.
2A). In the patients who continued deferasirox therapy
in the extension study, serum ferritin levels continued
to decrease with a median reduction of 63.5% (P ¼
0.002), 74.8% (P < 0.0001), and 74.1% (P ¼
0.0004) from the core baseline in the 5, 10, and 15
mg/kg/day cohorts, respectively (Fig. 2B). However, it
should be noted that six of the nine patients in the 5
mg/kg/day cohort received an increased dose of 10
mg/kg/day during the extension. Changes in serum
ferritin levels at the end of the core study were not
statistically different at a 0.05 level between the three
dose cohorts. Longitudinal analysis over the core and
extension study showed that the reduction in serum
ferritin from baseline levels was signiﬁcantly greater in
the 10 and 15 mg/kg/day cohorts compared with the
5 mg/kg/day cohort (P < 0.05 for both). There was
no signiﬁcant difference in serum ferritin level decrease
between the 10 and 15 mg/kg/day cohorts. Reductions
in transferrin saturation were also observed in the core
study across all three dose cohorts, with a mean
decrease of 6.4%, 10.7%, and 2.1% in the 5, 10, and
15 mg/kg/day cohorts, respectively. In the patients
who continued deferasirox therapy in the extension
study, transferrin saturation continued to decrease in
the 10 and 15 mg/kg/day cohorts, resulting in a mean
decrease from baseline to the end of the extension by
14.4% and 12.1%, respectively. However, the overall
mean change from baseline in the 5 mg/kg/day cohort
was þ0.9%.
Relationship Between Serum Ferritin and Hepatic/
Renal Parameters. Subsequent analyses were performed
to evaluate the relationship between baseline serum
ferritin levels and changes in ALT and serum creat-
inine levels. These analyses suggested that ALT
and serum creatinine increases may have been
associated with relative deferasirox doses that were
too high compared with baseline serum ferritin levels
(Fig. 3).
Five of the six patients in the 15 mg/kg/day cohort
who had ALT levels >3  baseline and greater than
ULN had relatively low serum ferritin levels at baseline
(range 356-740 ng/mL). Two of these patients had
sharp rises in ALT concentration associated with rapid
reductions in serum ferritin to 70 and 108 ng/mL at
week 6 and 36, respectively. The sixth patient had a
baseline serum ferritin value of 1083 ng/mL, but expe-
rienced a rapid reduction at week 4 to 758 ng/mL.
The patient in the 5 mg/kg/day cohort who had an
ALT elevation of >3  baseline and greater than ULN
had a baseline serum ferritin value of 740 ng/mL, and
at the time of reaching the ALT elevation, had experi-
enced a reduction in serum ferritin levels to 83 ng/mL
following an increase in deferasirox dose (Fig. 4A).
The patient in the 10 mg/kg/day cohort with increased
Table 3. Most Common Drug-Related AEs ( 10% of All Patients in Core or Extension)
Adverse Event
n (%)
5 mg/kg/day 10 mg/kg/day 15 mg/kg/day All Patients
Core (n 5 11) Ext (n 5 9) Core (n 5 15) Ext (n 5 6) Core (n 5 23) Ext (n 5 11) Core (n 5 49) Ext (n 5 26)
Diarrhea 1 (9.1) 0 4 (26.7) 0 9 (39.1) 1 (9.1) 14 (28.6) 1 (3.8)
Increased serum creatinine* 0 1 (11.1) 3 (20.0) 1 (16.7) 4 (17.4) 1 (9.1) 7 (14.3) 3 (11.5)
Nausea 0 0 2 (13.3) 0 4 (17.4) 0 6 (12.2) 0
Abdominal pain 0 0 2 (13.3) 0 3 (13.0) 0 5 (10.2) 0
Increased ALT* 0 1 (11.1) 3 (20.0) 0 2 (8.7) 0 5 (10.2) 1 (3.8)
*Reported based on clinical signs or symptoms, considered clinically signiﬁcant by investigator or required therapy as a result.
Table 4. Serum Creatinine and Liver Function Tests
Core and Extension* 5 mg/kg/day (n 5 11) 10 mg/kg/day (n 5 15) 15 mg/kg/day (n 5 23) All Patients (n 5 49)
Serum creatinine, increase >33% above baseline
and >ULN at 2 consecutive visits, n (%)
0 5 (33.3) 8 (34.8) 13 (26.5)
AST
Increase >3  baseline and >ULN, n (%) 1 (9.1) 2 (13.3) 5 (21.7) 8 (16.3)
Increase >5  baseline and >ULN, n (%) 0 0 5 (21.7) 5 (2.0)
ALT
Increase >3  baseline and >ULN, n (%) 1 (9.1) 1 (6.7) 6 (26.1) 8 (16.3)
Increase >5  baseline and >ULN, n (%) 0 0 5 (21.7) 5 (2.0)
*Patients were counted only once in the core or extension.
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not show any distinct relationships between serum fer-
ritin and ALT increases.
Four of the ﬁve patients in the 10 mg/kg/day cohort
who had serum creatinine levels >33% above baseline
and greater than ULN at two consecutive visits had
relatively low baseline serum ferritin levels (range 587-
743 ng/mL); the remaining patient had a baseline se-
rum ferritin value of 1316 ng/mL, but experienced a
rapid reduction to 174 ng/mL by week 14. Baseline
serum ferritin levels were similarly low in six of the
eight patients in the 15 mg/kg/day cohort (range 490-
896 ng/mL); the other two patients had rapid reduc-
tions in serum ferritin values from 1018 to 494 ng/
mL at week 4 and from 1186 to 523 ng/mL at week
24, respectively. Overall in both dose cohorts, initial
notable increases in serum creatinine levels correspond-
ing with reductions in serum ferritin were observed
early (within 4-6 weeks) in seven patients. The
remaining six patients had serum creatinine increases
by the end of the 24-week core study. One patient in
the 15 mg/kg/day cohort had notable serum creatinine
increases on several occasions in association with
reductions in serum ferritin. On each of these
Fig. 2. Median serum ferritin in (A) patients enrolled in the core
study and (B) patients who completed the core and continued into the
extension study. BL, baseline. Note that the 5 mg/kg/day dose
reduced serum ferritin in three patients; the other six patients in this
dose cohort received 10 mg/kg/day at the start of the extension (all
but one patient experienced serum ferritin levels <100 ng/mL when
receiving 10 mg/kg/day).
Fig. 3. Scatter plots of baseline
serum ferritin versus worst ALT rela-
tive change (%) during (A) 24
weeks of treatment and (B) 48
weeks of treatment; and worst se-
rum creatinine relative change (%)
during (C) 24 weeks of treatment
and (D) 48 weeks of treatment, by
dose cohort and ULN.
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line levels after deferasirox was temporarily discontin-
ued (Fig. 4B).
Discussion
This is the ﬁrst clinical trial to demonstrate the
safety and efﬁcacy of deferasirox in a population of
patients with C282Y homozygous HH and primary
iron overload. There was higher enrollment of males
than females as expected, because female C282Y
homozygotes tend to have lower levels of iron overload
than male homozygotes.
19 Although phlebotomy is the
ﬁrst line of treatment for patients with HH, these data
indicate that chelation therapy with deferasirox may
offer an alternative approach to the management of
iron accumulation for patients who are unwilling or
unable to comply with de-ironing by phlebotomy. The
results from the 24-week core study demonstrated that
the AE proﬁle was consistent with the known safety
proﬁle of deferasirox; all described gastrointestinal, re-
nal, and hepatic AEs are known, labeled, and are clini-
cally manageable with regular patient monitoring as
reported in patients with transfusion-induced iron
overload. The frequency of AEs was dose-dependent,
being highest in the 15 mg/kg/day patient cohort; the
estimated incidence of AEs at 20 mg/kg/day precluded
dose escalation beyond 15 mg/kg/day. AEs generally
occurred early during treatment as shown by the
higher frequency reported during the core compared
with the extension study. However, these data could be
limited by the potential for self-selection of patients;
for example, it is possible that patients experiencing
AEs in the core phase of the study decided not to con-
tinue in the extension, reﬂecting the reduced frequency
of AEs reported.
Deferasirox doses of 5, 10, and 15 mg/kg/day
reduced serum ferritin levels in this population of
patients with HH, although it should be noted that six
of the nine patients in the 5 mg/kg/day cohort who
entered the extension study were dose escalated to 10
mg/kg/day. The percentage change in serum ferritin
level was greater in the 10 and 15 mg/kg/day cohorts
compared with the 5 mg/kg/day cohort and similar in
the 10 and 15 mg/kg/day cohorts. When considered
together with the safety results, where a higher fre-
quency of AEs were reported in the 15 mg/kg/day
cohort, a starting dose of 10 mg/kg/day appears to be
the most appropriate in this population of patients.
This is a starting dose lower than that generally recom-
mended for patients with transfusional iron
overload.
7,10,20
Subsequent analyses of these data suggested that no-
table changes in renal and liver laboratory safety data
were reﬂective of changes in serum ferritin levels over
the course of the study, particularly in the 10 and 15
mg/kg/day cohorts. Several patients with low baseline
serum ferritin levels, or those who experienced rapid
reductions in serum ferritin, had notable increases in
ALT or serum creatinine levels that required dose mod-
iﬁcations and/or interruptions; there was no clear rela-
tionship between the occurrence of these laboratory
abnormalities and time on study. A risk of AEs,
including renal disorder following over-rapid chelation,
has also been identiﬁed in transfusion-dependent
patients and particular attention is advised for moni-
toring of serum creatinine levels in patients who are
receiving high doses of deferasirox with low rates of
transfusion.
20,21 These data suggest that appropriate
target serum ferritin levels should be predeﬁned and
rapid iron depletion is to be avoided in order to pre-
vent the occurrence of AEs, particularly because many
patients may be asymptomatic. This can be achieved
by closely monitoring body iron levels and adjusting
deferasirox doses accordingly. Serial measurement of
serum ferritin levels is a convenient and inexpensive
tool that has been widely used for monitoring body
iron levels and the efﬁcacy of chelation therapy in vari-
ous transfusion-dependent anemias.
10,20 Although no
conclusive mechanistic explanation for the increases in
serum creatinine observed in this study is available yet,
Fig. 4. Individual patient examples of the relationship between se-
rum ferritin and (A) ALT and (B) serum creatinine.
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a result of deferasirox therapy.
22,23 Although not an in-
tegral part of the protocol in the present study, serum
creatinine levels in a limited number of patients who
were monitored after treatment returned to normal. In
addition, data from transfusion-dependent patient
populations have shown that renal and hepatic events
are generally nonprogressive and return to within nor-
mal limits following drug discontinuation.
20,24,25
The incidence of AEs, particularly in the core study,
was slightly higher than that observed in patients with
transfusional iron overload,
20 although the lower num-
ber of patients included in this phase 1/2 trial should
be considered. Our data suggest this difference may be
related to the lower levels of iron burden in patients
with HH, as well as lower rates of iron accumulation
in the absence of ongoing red blood cell transfusions.
This is supported by the higher rate of serum creati-
nine and ALT level increases in patients with lower se-
rum ferritin levels or those with rapid reductions in se-
rum ferritin following chelation therapy. Furthermore,
as the patients in this study were generally asymptom-
atic, reported AEs may be comparatively higher due to
the lack of medical conditions at baseline in the ma-
jority of patients, as opposed to other patient popula-
tions studied with additional underlying medical prob-
lems. The incidence of AEs during therapy with
deferasirox may have implications for patient compli-
ance and ultimately, the acceptance of iron chelation
therapy for the treatment of patients with HH. In
addition, the ease, effectiveness, and relatively low cost
of phlebotomy therapy make it likely that phlebotomy
will remain the treatment of choice for the vast major-
ity of patients with HH.
Although phlebotomy and iron chelation therapy
are effective for reducing iron burden in patients with
HH, natural history studies of untreated C282Y
homozygotes have demonstrated that progressive iron
accumulation does not always occur.
26-29 As such, fur-
ther consideration should also be given to the identiﬁ-
cation of suitable candidates for therapy
30 by monitor-
ing serum ferritin levels prior to and during any
subsequent treatment.
Some of the limitations of this study were that
many of the patients had mild iron overload as
assessed by serum ferritin levels, and a number of
patients were treated with chelation therapy after hav-
ing previously received phlebotomy. This was a phase
1/2 dose ﬁnding and safety assessment study of defera-
sirox in patients with HH, and as such the study
involved a small number of patients. Therefore, further
studies in larger numbers of patients with HH and
assessments of the effects of de novo iron chelation
therapy would be of value.
In conclusion, the ﬁndings reported here on the use
of deferasirox to reduce iron in patients with nontrans-
fusional iron overload due to HH are encouraging.
Based on the safety and efﬁcacy results, a starting dose
of 10 mg/kg/day appears to be the most appropriate
in this population; close monitoring of renal and he-
patic function is required, especially in patients with
lower body-iron burdens. Larger studies are warranted
to more fully deﬁne the appropriate role of deferasirox
for the treatment of selected patients.
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